Assembly Biosciences, Inc. (ASMB)
NASDAQ: ASMB · Real-Time Price · USD
24.64
+0.65 (2.71%)
At close: Aug 13, 2025, 4:00 PM
24.55
-0.20 (-0.81%)
Pre-market: Aug 14, 2025, 4:38 AM EDT
Assembly Biosciences Employees
Assembly Biosciences had 73 employees as of December 31, 2024. The number of employees increased by 8 or 12.31% compared to the previous year.
Employees
73
Change (1Y)
8
Growth (1Y)
12.31%
Revenue / Employee
$455,438
Profits / Employee
-$533,753
Market Cap
383.40M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ASMB News
- 5 days ago - Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts - Seeking Alpha
- 6 days ago - Assembly Biosciences Announces Pricing of $175 Million in Equity Financings - GlobeNewsWire
- 6 days ago - Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes - GlobeNewsWire
- 7 days ago - Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates - GlobeNewsWire
- 7 days ago - Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus - GlobeNewsWire
- 19 days ago - Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop - GlobeNewsWire
- 6 weeks ago - Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179 - GlobeNewsWire
- 7 weeks ago - Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B - GlobeNewsWire